Derazantinib is under investigation in clinical trial NCT03230318 (Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma).
MVZ am Oskar-Helene Heim Berlin, Berlin, Germany
Universitätsmedizin Mannheim, Mannheim, Germany
Vivantes Klinikum Berlin Friedrichshain, Berlin, Germany
Tomsk Research Instutite of Oncology, Tomsk, Russian Federation
MD Anderson Cancer Centre, Madrid, Spain
Liga Norte-Rio-Grandense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil
Antwerp University Hospital, Edegem, Belgium
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Mayo Clinic, Rochester, Minnesota, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.